Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma

• DOI: 10.1126/scitranslmed.aal2668
• Publication Date: 2017-05-11T13:56:03Z
• Authors: Salomon Manier; Daisy Huynh; Yu J. Shen; Jia Zhou; Timur Yusufzai; Karma Z. Salem; Richard Y. Ebright; Jiantao Shi; Jihye Park; Siobhan V. Glavey; William G. Devine; Chia-Jen Liu; Xavier Leleu; Bruno Quesnel; Catherine Roche-L...; John K. Snyder; Lauren E. Brown; Nathanael Gray; James Bradner; Luke Whitesell; John A. Porco; Irene M. Ghobrial
• Keywords: Medical and health sciences; 0301 basic medicine; 570; 610; Xenograft Model Antitumor Assays; 3. Good health; Proto-Oncogene Proteins c-myc; Biological sciences; Mice; 03 medical and health sciences; Cell Line, Tumor; Proto-Oncogene Proteins c-maf; Animals; Humans; Cyclin D1; Multiple Myeloma

Targeting translation initiation in multiple myeloma induces inhibition of a specific oncogenic translation program.